Report cover image

Axillary Hyperhidrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Jun 30, 2022
Length 43 Pages
SKU # GMD17341260

Description

Axillary Hyperhidrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis – Drugs In Development, 2022, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 1 and 1 respectively.

Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

43 Pages
Introduction
Global Markets Direct Report Coverage
Axillary Hyperhidrosis – Overview
Axillary Hyperhidrosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Axillary Hyperhidrosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Axillary Hyperhidrosis – Companies Involved in Therapeutics Development
Botanix Pharmaceuticals Ltd
Dermata Therapeutics Inc
Dermavant Sciences Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Medytox Inc
Revance Therapeutics Inc
Axillary Hyperhidrosis – Drug Profiles
(oxybutynin + pilocarpine) – Drug Profile
DMT-410 – Drug Profile
glycopyrrolate – Drug Profile
nivobotulinumtoxin A – Drug Profile
onabotulinumtoxinA biosimilar – Drug Profile
sofpironium bromide – Drug Profile
Axillary Hyperhidrosis – Dormant Projects
Axillary Hyperhidrosis – Discontinued Products
Axillary Hyperhidrosis – Product Development Milestones
Featured News & Press Releases
Mar 10, 2022: Brickell Biotech selected for a late-breaking oral presentation of US phase 3 pivotal cardigan I and Cardigan II study results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting
Nov 19, 2021: Dermata announces positive results from DMT410 phase 1b proof of concept study for aesthetic skin conditions
Nov 12, 2021: Dermata announces presentation details for its DMT410 phase 1b proof of concept aesthetic study at the American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
Nov 11, 2021: Dermata announces virtual investor event to present DMT410 phase 1b proof of concept results in aesthetic skin conditions
Oct 07, 2021: Brickell Biotech announces positive topline results, achieving statistical significance on all primary and secondary endpoints, from both U.S. Phase 3 pivotal clinical studies of Sofpironium Bromide Gel, 15% in primary axillary hyperhidrosis patients
Sep 21, 2021: Dermata to present results from its DMT410 phase 1b proof of concept aesthetic study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
Aug 16, 2021: Brickell Biotech announces final patient completed second U.S. phase 3 pivotal clinical study of sofpironium bromide gel, 15% for the treatment of primary axillary hyperhidrosis
Jun 29, 2021: Brickell Biotech announces final patient completed in first U.S. phase 3 pivotal clinical study and patient enrollment completed in second U.S. phase 3 pivotal clinical study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis
Jun 24, 2021: Brickell Biotech announces initiation of a phase 1 study of Sofpironium Bromide Gel in primary palmoplantar hyperhidrosis patients by its development partner, Kaken Pharmaceutical in Japan
Jun 01, 2021: Brickell Biotech announces publication of Japan phase 3 long-term safety and efficacy study results for Sofpironium Bromide Gel, 5% (ECCLOCK) in the Journal of Dermatology
Apr 27, 2021: Brickell Biotech completes patient enrollment in U.S. phase 3 pivotal Cardigan I study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis
Apr 23, 2021: Brickell Biotech reports results from U.S. phase 3 open-label, long-term safety study on chronic use of sofpironium bromide gel as a potential treatment for primary axillary hyperhidrosis
Apr 16, 2021: Brickell Biotech announces presentation of US phase 3 open-label long-term safety study results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX
Apr 15, 2021: Brickell Biotech announces publication of its HDSM-Ax patient reported outcome scale validation results in the Journal of Drugs in Dermatology
Mar 05, 2021: Brickell Biotech to host key opinion leader webinar on the hyperhidrosis market
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Axillary Hyperhidrosis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Products under Development by Companies, 2022
Table 4: Number of Products by Stage and Target, 2022
Table 5: Number of Products by Stage and Mechanism of Action, 2022
Table 6: Number of Products by Stage and Route of Administration, 2022
Table 7: Number of Products by Stage and Molecule Type, 2022
Table 8: Axillary Hyperhidrosis – Pipeline by Botanix Pharmaceuticals Ltd, 2022
Table 9: Axillary Hyperhidrosis – Pipeline by Dermata Therapeutics Inc, 2022
Table 10: Axillary Hyperhidrosis – Pipeline by Dermavant Sciences Inc, 2022
Table 11: Axillary Hyperhidrosis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, 2022
Table 12: Axillary Hyperhidrosis – Pipeline by Medytox Inc, 2022
Table 13: Axillary Hyperhidrosis – Pipeline by Revance Therapeutics Inc, 2022
Table 14: Axillary Hyperhidrosis – Dormant Projects, 2022
Table 15: Axillary Hyperhidrosis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Axillary Hyperhidrosis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Targets, 2022
Figure 4: Number of Products by Stage and Targets, 2022
Figure 5: Number of Products by Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us